Literature DB >> 16783394

Development and characterization of a cholangiocyte cell line from the PCK rat, an animal model of Autosomal Recessive Polycystic Kidney Disease.

Melissa A Muff1, Tatyana V Masyuk, Angela J Stroope, Bing Q Huang, Patrick L Splinter, Seung-Ok Lee, Nicholas F Larusso.   

Abstract

In the PCK rat, a rodent model of Autosomal Recessive Polycystic Kidney Disease (ARPKD), a spontaneous splicing mutation of Pkhd1 initiates hepatic cyst development. Cystic cholangiocytes possess short and malformed cilia that do not express fibrocystin, the Pkhd1 protein. During the disease course, cysts continue to grow; however, the mechanisms underlying cyst progression are unclear due in part to the lack of suitable cell lines to study cystogenesis. Here, we describe the development of a PCK-derived cholangiocyte cell line (PCK-CCL). Normal rat cholangiocytes (NRCs) were used as a control. The PCK-CCL maintained a cholangiocyte phenotype as assessed by the expression of the CK-19, CK-7 and GGT. PCK-CCL grown on collagen formed a polarized monolayer with well-developed junctional complexes, and distinct apical and basolateral membranes. Compared to NRCs, cilia in the PCK-CCL were short and malformed and did not express fibrocystin. The PCK-CCL exhibited a higher rate of proliferation (P<0.05) with a doubling time approximately half that of NRCs. By RT-PCR analysis of exons 33-37, an approximately 800 bp product of Pkhd1 was amplified in NRCs. In contrast and as expected, in the PCK-CCL, the Pkhd1 amplicon was smaller ( approximately 630 bp) reflecting the IVS35-2A --> T mutation. PCK-CCL and NRCs seeded in 3-D cultures formed cystic structures; however, the PCK cysts expanded progressively up to day 21 while cysts formed by NRCs remained the same size after day 9. In summary, we have developed a cholangiocyte cell line from the PCK rat that retains properties of the cholangiocytes lining hepatic cysts in vivo. The cells have been grown continuously for approximately 18 month and 45 passages without crisis or senescence. The morphology and growth characteristics of the PCK-CCL are consistent with those seen in vivo in the PCK rat, suggesting that this cell line will be useful in dissecting the mechanisms of hepatic cyst formation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16783394     DOI: 10.1038/labinvest.3700448

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  23 in total

1.  Immortalized liver endothelial cells: a cell culture model for studies of motility and angiogenesis.

Authors:  Robert C Huebert; Kumaravelu Jagavelu; Ann F Liebl; Bing Q Huang; Patrick L Splinter; Nicholas F LaRusso; Raul A Urrutia; Vijay H Shah
Journal:  Lab Invest       Date:  2010-07-19       Impact factor: 5.662

2.  Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion.

Authors:  Sergio A Gradilone; Anatoliy I Masyuk; Patrick L Splinter; Jesus M Banales; Bing Q Huang; Pamela S Tietz; Tatyana V Masyuk; Nicholas F Larusso
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-16       Impact factor: 11.205

3.  Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

Authors:  Patricia Munoz-Garrido; José J G Marin; María J Perugorria; Aura D Urribarri; Oihane Erice; Elena Sáez; Miriam Úriz; Sarai Sarvide; Ainhoa Portu; Axel R Concepcion; Marta R Romero; María J Monte; Álvaro Santos-Laso; Elizabeth Hijona; Raúl Jimenez-Agüero; Marco Marzioni; Ulrich Beuers; Tatyana V Masyuk; Nicholas F LaRusso; Jesús Prieto; Luis Bujanda; Joost P H Drenth; Jesús M Banales
Journal:  J Hepatol       Date:  2015-06-01       Impact factor: 25.083

4.  Increased YAP Activation Is Associated With Hepatic Cyst Epithelial Cell Proliferation in ARPKD/CHF.

Authors:  Lu Jiang; Lina Sun; Genea Edwards; Michael Manley; Darren P Wallace; Seth Septer; Chirag Manohar; Michele T Pritchard; Udayan Apte
Journal:  Gene Expr       Date:  2017-09-15

Review 5.  Animal models of biliary injury and altered bile acid metabolism.

Authors:  Valeria Mariotti; Mario Strazzabosco; Luca Fabris; Diego F Calvisi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-11       Impact factor: 5.187

6.  Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.

Authors:  Sergio A Gradilone; Tatyana V Masyuk; Bing Q Huang; Jesus M Banales; Guillermo L Lehmann; Brynn N Radtke; Angela Stroope; Anatoliy I Masyuk; Patrick L Splinter; Nicholas F LaRusso
Journal:  Gastroenterology       Date:  2010-04-14       Impact factor: 22.682

7.  Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.

Authors:  Aura D Urribarri; Patricia Munoz-Garrido; María J Perugorria; Oihane Erice; Maite Merino-Azpitarte; Ander Arbelaiz; Elisa Lozano; Elizabeth Hijona; Raúl Jiménez-Agüero; Maite G Fernandez-Barrena; Juan P Jimeno; Marco Marzioni; Jose J G Marin; Tatyana V Masyuk; Nicholas F LaRusso; Jesús Prieto; Luis Bujanda; Jesús M Banales
Journal:  Gut       Date:  2014-01-16       Impact factor: 23.059

8.  HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.

Authors:  Sergio A Gradilone; Stefan Habringer; Tatyana V Masyuk; Brynn N Howard; Anatoliy I Masyuk; Nicholas F Larusso
Journal:  Am J Pathol       Date:  2014-01-13       Impact factor: 4.307

9.  Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.

Authors:  Jesús M Banales; Tatyana V Masyuk; Pamela S Bogert; Bing Q Huang; Sergio A Gradilone; Seung-Ok Lee; Angela J Stroope; Anatoliy I Masyuk; Juan F Medina; Nicholas F LaRusso
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

10.  Demonstration of primary cilia and acetylated α-tubulin in fish endothelial, epithelial and fibroblast cell lines.

Authors:  Nguyen T K Vo; Niels C Bols
Journal:  Fish Physiol Biochem       Date:  2015-08-07       Impact factor: 2.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.